About: Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the stratification and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up in microhematuria patients; Cxbladder Detect, which improve practice workflow and efficiency in urological care; Cxbladder Triage Plus, a non-invasive surveillance alternative that can reduce the burden of repeated cystoscopy in patients; and Cxbladder Monitor, a non-invasive surveillance alternative that reduces the burden of repeated cystoscopy in patients with a recurrent non-muscle invasive bladder cancer. In addition, the company is developing products for bladder, gastric, colorectal and endometrial cancers, and melanoma. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.
Sector: Healthcare
Industry: Diagnostics & Research
Latest price: A$0.19 (-5.00%)
PEB ASX Pacific Edge Ltd
Pacific Edge Ltd share price
PEB price activity
Último preço
$ 0,190
Variação (24h)
-0,01 AUD (-5,00%)
Volume
753
Volume (média 4 sem.)
-
Abertura
$ 0,19
Variação do dia
$ 0,19 - $ 0,19
Fechamento anterior
$ 0,20
Último negócio
04 Oct, 11:00 pm GMT+0
Atrasado
04 Oct, 11:00 pm GMT+0
PEB price performance
Atrasado
04 Oct, 11:00 pm GMT+0
quote.marketSignals